Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation
Completed · Phase 3 · Has a placebo group
Conditions studied: Inflammation, Pain, Cataract
In brief
The purpose of this study is to evaluate the clinical efficacy and safety of XG-102 (900µg) compared to vehicle in the treatment of subjects with inflammation and pain following cataract surgery.
Key facts
- Study ID
- NCT02235272
- Run by
- Xigen SA
- People needed
- 339
- Starts
- 2014-09-01
- Expected to finish
- 2015-12-01
- Last updated by the study team
- 2017-01-24
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Study site — Garden Grove, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.